Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$33.8 - $47.06 $17.2 Million - $24 Million
-509,408 Reduced 51.39%
481,853 $20.4 Million
Q3 2022

Nov 10, 2022

SELL
$31.52 - $373.61 $13.5 Million - $160 Million
-427,273 Reduced 30.12%
991,261 $31.8 Million
Q2 2022

Aug 12, 2022

SELL
$26.83 - $38.57 $26.4 Million - $37.9 Million
-982,746 Reduced 40.93%
1,418,534 $46.1 Million
Q1 2022

May 13, 2022

SELL
$30.95 - $39.68 $7.57 Million - $9.7 Million
-244,461 Reduced 9.24%
2,401,280 $86.9 Million
Q4 2021

Feb 11, 2022

SELL
$35.87 - $47.12 $4.54 Million - $5.96 Million
-126,587 Reduced 4.57%
2,645,741 $105 Million
Q3 2021

Nov 12, 2021

SELL
$41.55 - $48.72 $20.3 Million - $23.8 Million
-488,554 Reduced 14.98%
2,772,328 $121 Million
Q2 2021

Aug 12, 2021

SELL
$32.88 - $44.57 $1.75 Million - $2.38 Million
-53,300 Reduced 1.61%
3,260,882 $133 Million
Q1 2021

May 11, 2021

SELL
$30.92 - $44.4 $19.3 Million - $27.7 Million
-623,692 Reduced 15.84%
3,314,182 $109 Million
Q4 2020

Feb 10, 2021

SELL
$33.66 - $40.76 $10.7 Million - $13 Million
-318,132 Reduced 7.47%
3,937,874 $160 Million
Q3 2020

Nov 12, 2020

SELL
$33.07 - $38.68 $2.58 Million - $3.02 Million
-77,974 Reduced 1.8%
4,256,006 $156 Million
Q2 2020

Aug 12, 2020

BUY
$20.05 - $33.89 $15.3 Million - $25.9 Million
764,571 Added 21.42%
4,333,980 $147 Million
Q1 2020

May 12, 2020

SELL
$17.15 - $25.22 $2.82 Million - $4.15 Million
-164,714 Reduced 4.41%
3,569,409 $75.6 Million
Q4 2019

Feb 12, 2020

SELL
$18.88 - $24.14 $2.11 Million - $2.7 Million
-111,988 Reduced 2.91%
3,734,123 $83.4 Million
Q3 2019

Nov 12, 2019

BUY
$18.0 - $21.38 $69.2 Million - $82.2 Million
3,846,111 New
3,846,111 $77.9 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $12.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Artisan Partners Limited Partnership Portfolio

Follow Artisan Partners Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Artisan Partners Limited Partnership with notifications on news.